All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

Filed in Bank Gold, EPS, o, revenue, target by on February 8, 2011 0 Comments

Filed under: Newsletters , Stocks to Buy “The visible growth story at Jazz Pharmaceuticals ( JAZZ ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues,” says growth stock specialist Mike Cintolo . The editor of Cabot Top Ten Weekly Report explains, “But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain. “Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome. Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds . Permalink | Email this | Comments

Read the original post:
All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

Tags: , , , , , , , , , , , , ,

About the Author ()

Leave a Reply

Your email address will not be published. Required fields are marked *